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IMMUNOHISTOCHEMICAL STUDY OF HUMAN MALIGNANT
MELANOMA FOR THE PRESENCE OF GAMMA GLOBULIN*
ALFRED W. KOPF, M.D.t, INGA SILBERBERG, M.D.t
AND NORMAN S. COOPER, M.D.t
Tumors may contain antigens not present
elsewhere in the animal or patient in which they
arise (1—7). If some tumor cells contain antigens
foreign to the host, it is theoretically possible
that the host can respond immunologically with
either circulating or cellular antibodies directed
against these substances (8—12). If patients
with malignant melanoma react with the pro-
duction of circulating antibodies to their tu-
mors, it might be that such antibodies could he
demonstrated with the fluorescent antibody
method.
We had the occasion to study a patient who
demonstrated involution of some of his cutane-
ous malignant melanoma metastases (13). Since
otbers have suggested that serum factors may
play a role in such tumor involution (14, 15),
the presence of gamma globulin was studied in
this patient's tumors and in other primary and
metastatic human malignant melanomas.
MATERIALs AND METHOD5
1. Preparation of gamma globulin.—Human 75
gamma globulin was prepared from serum by pre-
cipitation with saturated ammonium sulfate. This
precipitate was redissolved in 0.01 M phosphate
buffer pH 8.6 and dialyzed against the same buffer
overnight at 40 C. An anion exchanger, diethyl-
aminoetbyl (DEAE) cellulose, was prepared by
the method of Levy and Sober (16). After
equilibration with 0.01 M phosphate pH 7.0 buffer,
the exchanger was packed into a glass column un-
der mild air pressure. For every 60 mg of protein
placed on the column, 1 gm of DEAE cellulose
was used. The crude gamma globulin, equilibrated
at 0.01 ii phosphate buffer pH 8.6, was then placed
on the column and eluted with 0.01 at phosphate
buffer pH 7.0. The effluent was collected as 4 ml
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fractions and the relative protein content of each
fraction was determined by measurement of ul-
traviolet absorption at 280 mu in a Beckman DB
spectrophotometer. The purity of the 78 gamma
globulin was checked by immunoeleetrophoretic
analysis (17).
2. Preparation of rabbit antihuman gamma
globulin—Albino rabbits weighing about 2.5 kilo-
grams each were injected subcutaneously in the
interscapular area with 10 mg of human 7S
gamma globulin homogenized with 0.1 ml of com-
plete Freund's adjuvant (Difco). Then 1.5 mg
gamma globulin was injected intravenously three
times a week for one week, followed by 2.0 mg
three times a week for 3 to 15 weeks. One week
after the last injection, the rabbits were bled. A
qualitative precipitin ring test and immunoelea-
tropboretic analysis were performed (17).
3. Fluorescein conjugation of antiserum .—T he
78 gamma globulin portion of the rabbit serum
was isolated using the above outlined procedure.
This portion was added to 0.05 at sodium carbon-
ate-bicarbonate buffer pH 9.0 and conjugated
with fluorescein isothiocyanate (FITC) on celite*
by the method of Rinderknecht (18). For each
1000 mg protein about 18 mg FITC was used. The
mixture was mechanically stirred until all the
FITC was uniformly dispersed. It was then cen-
trifuged at 40 C for thirty minutes and the pre-
cipitate was discarded. To obviate non-specific
staining and to remove uncombined fluorescein,
the 78 gamma globulin conjugate was dialyzed at
40 C overnight against 0.125 iii NaCl in 0.0175 at
phosphate buffer pH 6.3. A DEAE cellulose
column was again prepared as above, but now it
was equilibrated with 0.125 at NaCI in 0.0175 at
phosphate buffer pH 6.3. The exchanger was
packed in a glass column and the conjugate eluted
with the same buffer (19). After determination
of protein and fluorescein content of each aliquot
by their optical densities at 280 mu and 490 mu
respectively, aliquots showing the highest protein
and dye concentration were combined and dia-
lyzed overnight at 40 C against phosphate buffered
saline pH 7.5.
Unconjugated 7S gamma globulin was also
dialyzed overnight at 40 C against phosphate buff-
ered saline pH 7.5. Concentration of fractions
was then carried out so that the amount of protein
was about 10 mg per ml.
4. Processing of biopsy specimens—Several cu-
taneous metastatic nodules from the patient who
showed involution of some of the lesions and a
* California Corporation for Biochemical Re-
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number of other primary and metastatic malig-
nant melanoma nodules from other patients *
were obtained surgically. In all, thirteen human
malignant melanomas were studied. Of these, three
were amelanotic and ten melanotic; six were pri-
mary and seven metastatic.
Control specimens included the following: 5
normal skin; 2 compound nevi; 6 halo nevi; 2
keratoacanthoma; 1 granuloma pyogenicum; 1
basal cell epithelioma; 1 nodulus cutaneous; 1
prickle cell epithelioma; and 1 juvenile melanoma.
Immediately after excision the specimens were
wrapped in aluminum foil and dropped into liquid
nitrogen for one minute. Sections 2 to 6 microns
thick were cut in a cryostat and placed on glass
slides. These sections were then dried at room
temperature for one hour, fixed in acetone for
ten minutes and stored at —20° C until ready fur
staining by the fluorescent antibody method. Alter-
nate sections were stained with hematoxylin and
eosin or toluidine blue to correlate light micros-
copy findings with those of fluorescence microscopy.
5. Staining of tissue sections with the fluoreseein
conjugates.—Cryostat-cut sections were washed in
buffered saline pH 7.5 for thirty minutes and then
flooded with fluorescein conjugated rabbit anti-
human gamma globulin for thirty minutes. Other
cryostat-cut sections were flooded with the serum
of patients with malignant melanoma or control
serums obtained from 10 normal subjects and
from patients with other skin tumors, e.g., kerato-
acanthoma and halo nevus. After thirty minutes
the sections were washed and fluorescein conju-
gated rabbit antihuman gamma globulin applied
for thirty minutes. The sections were washed with
buffered saline (5 minutes >< 4). The following
procedures were carried out to determine the speci-
ficity of staining:
1. Some sections were treated with unconfugated
rabbit antihuman gamma globulin prior to
staining with the fluorescein conjugated rab-
bit antihuman gamma globulin (blocking).
2. Other sections were stained with a fluorescein-
conjugated rabbit antihuman gamma globulin
which had been absorbed previously with
human gamma globulin.
3. Still other sections were flooded with fluo-
rescein-conj ugated normal (preimmunization)
rabbit serum.
Following these control procedures the sections
were washed with buffered saline (5 minutes X 4).
A coverslip was placed over the tissue sections
using Coon's buffered glycerol as mounting me-
dium (20).
All slides were examined under a Leitz Or-
tholux fluorescence microscope using a 2 mm PG
I filter for UV light excitation and a 2.5 mm
Euphos eyepiece barrier filter. Photographs were
taken using Kodak high speed Ektachrome day-
light film.
RESULTS
The findings in the tumors obtained from the
patient with the involuting malignant mela-
noma lesions were similar to those of the other
tumors. Six malignant melanoma specimens in-
cluding lesions obtained from the aforemen-
tioned patient and 5 other patients contained
plasma cells whose cytoplasm stained brilliant
green with the fluorescein-conjugated rabbit
antihuman gamma globulin (Fig. 1). These cells
were sparsely distributed among the tumor cells
as well as in distant sites in the cutis and sub-
cutis. One Specimen had numerous groups of
plasma cells interspersed among sheets of the
malignant melanoma tissue. In another speci-
men, the presumed primary site in a patient
who had disseminated malignant melanoma
metastases, peculiar amorphous homogeneous
masses of material in the upper cutis stained
brilliant green. The following findings indicated
that the staining of the plasma cells and amor-
phous masses was specific for gamma globulin:
1. Treatment of the section with unconju-
gated rabbit antihuman gamma globulin
prior to staining with the fiuorescein con-
jugated rabbit antihuman gamma globulin
significantly diminished the green fluores-
cence.
2. Sections stained with fluorescein-conju-
gated rabbit antihuman gamma globulin
absorbed previously with human gamma
globulin showed no green fluorescence.
3. Fluorescein-conjugated normal rabbit se-
rum applied to tissue sections gave no
green fluorescence.
In five specimens brilliant green fluorescing
cells were seen, and were identified as mast cells
with toluidine blue stain in serial sections. The
above criteria for specificity of staining were
not met when these procedures were performed,
indicating that mast cell staining with this
method was nonspecific.
In three malignant melanoma specimens stud-
ied, nonspecific bright green fluorescence oc-
curred in the nuclear area of epidermal keratino-
cytes. Prior digestion with desoxyribonuclease
diminished, but failed to completely eliminate
this staining.
In none of the tumor specimens was human
gamma globulin found in or on the tumor cells.
Prior treatment of tissue sections with patient's
or control serums did not influence these nega-
tive results.
* Doctors Stephen L. Gumport, W. Robson N.
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Code:
FITC Fluorescein isothiocyanateRAHGG = Rabbit antihuman gamma globulin
FIG. 1. Section of a metastatic amelanotic malignant melanoma treated with FITC con-jugated RAHGO. )< 179. Shows: The cytoplasm of several mononuclear cells fluoresces
bright green. Nuclei are black. Cytoplasm of the tumor cells does not fluoresce green.
One of five specimens of normal skin, two
compound ncvi, five of six specimens of halo
ncvus, two kcratoacanthoma specimens, one
juvenile melanoma specimen and one prickle
cell epithelioma specimen also possessed scat-
tered plasma cells and/or mast cells which
stained brilliant green as above.
In one halo nevus specimen, nonspecific bright
green fluorescence occurred in the nuclear area
of epidermal keratinocytes.
DisCussiON
In the present study no IgG (78 gamma
globulin) was found in or on malignant mela-
noma cells. Furthermore, serums from patients
with malignant melanoma did not contain anti-
bodies detectable by this method, which would
specifically attach in vitro to tissue sections of
their tumors or to the tumors of other patients.
While the lack of gamma globulin on tumor cells
suggests that the patients' immunologic mecha-
nisms did not recognize these malignant cells
as foreign and therefore showed no detectable
immunological response, the following factors
must be considered before such an interpretation
can be made:
1. In an earlier stage of tumor formation
gamma globulin may have been present.
Subsequently, the persistence in the pa-
tient of large amounts of antigen (tumor)
over a long period might have resulted in a
state analogous to the experimentally in-
duced phenomenon of immune paralysis
(21).
2. Antibodies other than IgG were not specifi-
cally studied. It is known, however, that
most antiserums to IgG cross react with
1gM (19S) and IgA (B,A) unless they are
absorbed with fraction A or C or absorbed
with pure 1gM or IgA (22).
3. Antibody might not bave been detectable
because it was lost in processing or was
present in insufficient quantity to be stained
with our conjugates (23).
Six out of the 12 malignant melanomas stud-
ied had rare plasma cells and one specimen
showed numerous groups of plasma cells. Since
plasma cells play a role in antibody formation
(24), the possibility remains that these cells
were immunologically competent cells whose
globulin synthesizing machinery was directed
towards producing antitumor antibodies (9).
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However, from the experimental findings all
that was demonstrated was the presence of
gamma globulin containing plasma cells and it
can not be assumed that this is antibody directed
against the tumor. Furthermore, some of the
control tissues showed similar cells.
A presumed primary site in a patient with
metastatic malignant melanoma who was previ-
ously reported in detail (25) showed amor-
phous collections of gamma globulin in the up-
per dermis. The significance of this deposition
is unknown.
Mast cells contain granules which are capable
of nonspecific binding of fluorescein-conjugated
proteins (26). Such staining of mast cells has
been described previously (27).
The cause of the nonspecific nuclear fluores-
cence seen in some of the specimens studied re-
mains unexplained.
SUMMARY
The distribution of gamma globulin in thir-
teen human malignant melanomas including
those of a patient with involnting lesions, was
studied by the fluorescent antibody method.
Seven of the malignant melanomas contained
gamma globulin in plasma cells and/or large
mononuclear cells. Gamma globulin was not
detectable in or on the tumor cells. No gamma
globulin which would bind to sections of their
own tumors was found in the serums of patients
with malignant melanoma.
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